HUTCHMED (China) Limited (NASDAQ:HCM - Get Free Report)'s share price gapped up before the market opened on Thursday . The stock had previously closed at $14.41, but opened at $15.14. HUTCHMED shares last traded at $15.10, with a volume of 13,427 shares.
Separately, StockNews.com downgraded HUTCHMED from a "buy" rating to a "hold" rating in a report on Monday, November 18th.
Check Out Our Latest Analysis on HUTCHMED
The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.68 and a current ratio of 2.81. The firm has a 50 day simple moving average of $16.92 and a two-hundred day simple moving average of $17.90.
A number of large investors have recently modified their holdings of the company. State Street Corp boosted its holdings in HUTCHMED by 0.9% in the 3rd quarter. State Street Corp now owns 349,524 shares of the company's stock valued at $6,826,000 after purchasing an additional 3,078 shares during the period. M&G PLC boosted its stake in HUTCHMED by 98.1% during the third quarter. M&G PLC now owns 267,231 shares of the company's stock valued at $5,345,000 after buying an additional 132,333 shares during the period. Renaissance Technologies LLC increased its stake in HUTCHMED by 74.8% in the 2nd quarter. Renaissance Technologies LLC now owns 131,300 shares of the company's stock worth $2,248,000 after acquiring an additional 56,200 shares during the last quarter. Jane Street Group LLC boosted its position in shares of HUTCHMED by 362.2% during the 3rd quarter. Jane Street Group LLC now owns 62,997 shares of the company's stock valued at $1,305,000 after acquiring an additional 49,366 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. increased its position in shares of HUTCHMED by 99.0% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 48,724 shares of the company's stock worth $952,000 after purchasing an additional 24,245 shares during the last quarter. 8.82% of the stock is currently owned by institutional investors.
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.